The aim of the study was to evaluate the effect of vitamin D on the cognitive functions and quality of life in elderly and senile patients with cerebrovascular disease. 100 elderly and senile patients with cerebrovascular disease were examined: 60 people - level 25 (OH)D in blood serum <20 ng/ml (deficiency, pronounced deficiency), in 40 people this indicator was ≥30 ng/ml (within the normal range). Cognitive functions were evaluated according to neuropsychological scales (MMSE, MoCA, FAB, «clock drawing test», Schulte tables). To study the quality of life, all patients filled out a general questionnaire SF-36. The body's vitamin D supply was judged by the content of 25 (OH)D in the blood serum. Patients with low vitamin D levels (25 (OH)D <20 ng / ml) were divided into two subgroups: 30 people were prescribed cholecalciferol at a dosage of 8 000 IU/day for three months and 30 people who were not treated with cholecalciferol. The study showed that patients with low levels of vitamin D [25 (OH)D <20 ng/ml] had significantly worse indicators when assessing both cognitive functions and quality of life. The work proved that cognitive functions affect the quality of life. In patients with extremely low levels of vitamin D [25 (OH)D <20 ng/ml], after taking cholecalciferol at a dosage of 8000 IU/day for three months, there was a normalization of the level of 25 (OH)D (the average level of which was 34,10±7,42 ng/ml) in the blood serum and there was a significantly significant positive dynamics in assessing cognitive functions and quality of life.

Download full-text PDF

Source

Publication Analysis

Top Keywords

elderly senile
12
senile patients
8
patients cerebrovascular
8
cerebrovascular disease
8
[prevention cognitive
4
cognitive disorders
4
disorders elderly
4
senile patients]
4
patients] aim
4
aim study
4

Similar Publications

Biomarkers.

Alzheimers Dement

December 2024

Wisconsin Alzheimer's Disease Research Center, University of Wisconsin School of Medicine and Public Health, Madison, WI, USA.

Background: While magnetic resonance imaging (MRI) markers of neurodegeneration are nonspecific to Alzheimer's disease (AD) pathology, they have been correlated with cognitive dysfunction, and therefore, provide important information pertaining to disease staging. Neurodegeneration in AD is commonly assessed with macrostructural measures of brain atrophy, such as hippocampal volume. However, recent investigations have shown that markers of neural microstructure derived from diffusion MRI (DWI) may provide supplementary insight into the progression of AD pathophysiology.

View Article and Find Full Text PDF

Background: While several non-invasive plasma biomarkers are rapidly developing, they still have lower accuracy than the established CSF biomarkers. This study therefore comprehensively examined 6,905 plasma proteins in over 3,000 individuals to identify novel biomarkers for predicting clinical Alzheimer's disease (AD) and monitoring disease progression.

Method: To identify and validate plasma biomarkers, we performed difference abundance analysis of 6,905 plasma proteins in a total of 3,366 cases and controls from three different datasets (Knight-ADRC discovery, Knight-ADRC replication and Stanford ADRC).

View Article and Find Full Text PDF

Background: Alzheimer´s disease (AD) is the main neurodegenerative disorder and leading cause of dementia. AD neuropathology involves the extracellular formation of senile plaques with β-amyloid peptide and intraneuronal tau phosphorylation, leading to neurofibrillary tangle accumulation. These can be detected by biomarkers obtained from cerebrospinal fluid or Positron Emission Tomography (PET) using specific radiotracers.

View Article and Find Full Text PDF

Developing Topics.

Alzheimers Dement

December 2024

Neuro-Sys, Gardanne, France.

Background: Alzheimer's disease (AD) is characterized by the extracellular accumulation of senile plaques composed of beta-amyloid (Aβ) and the intracellular deposition of neurofibrillary tangles composed of hyperphosphorylated tau (Tp). Aβ induces a chronic neuroinflammation that contributes to the neurite network disorganization and finally neuronal death. Lecanemab, a humanized monoclonal antibody (Ab) that recognizes protofibrils/oligomers and prevents Aβ deposition, is the first US approved Ab for AD.

View Article and Find Full Text PDF

Background: Down syndrome (DS) is the most common and best-known chromosomal disorder in humans and the most frequent cause of intellectual disability of genetic origin, affecting about 6 million people worldwide. Individuals with DS may develop Alzheimer disease (AD) by age 55-60 years, and sometimes as young as 40 years due to the triplication of the amyloid β precursor protein (AβPP) gene, which is located on chromosome 21. The AD neuropathological phenotype in DS includes amyloid-β (Aβ) deposition (parenchymal and vascular) and neurofibrillary tangles comprised of tau protein.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!